Biosimilars and market access: A question of comparability and costs?

Targeted Oncology

Volumn 7, Issue 4, 2012, Pages 227-231

  Simoens, Steven ^a   Verbeken, Gilbert ^a,b   Huys, Isabelle ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b QUEEN ASTRID MILITARY HOSPITAL   (Belgium)

Author keywords

Biopharmaceutical; Biosimilar; Pricing; Registration; Reimbursement

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; BIOSIMILAR AGENT; GRANULOCYTE COLONY STIMULATING FACTOR; HUMAN GROWTH HORMONE; HYALURONIDASE; INSULIN; LOW MOLECULAR WEIGHT HEPARIN; MONOCLONAL ANTIBODY; NIVESTRIM; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT FOLLITROPIN; RECOMBINANT GLUCAGON; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GROWTH HORMONE; RECOMBINANT HYALURONIDASE; UNCLASSIFIED DRUG;

BIOEQUIVALENCE; CLINICAL TRIAL (TOPIC); COMPARATIVE STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG INDICATION; DRUG MARKETING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; FEBRILE NEUTROPENIA; HUMAN; NONHUMAN; PHARMACEUTICS; PRIORITY JOURNAL; REGISTRATION; REIMBURSEMENT; REVIEW;

BIOSIMILAR PHARMACEUTICALS; COST-BENEFIT ANALYSIS; DRUG DISCOVERY; EUROPE; HEALTH CARE SECTOR; HEALTH SERVICES ACCESSIBILITY; HUMANS; UNITED STATES;

EID: 84874472951     PISSN: 17762596     EISSN: 1776260X     Source Type: Journal    
DOI: 10.1007/s11523-011-0192-7     Document Type: Review

References (17)

1. Roger SD (2010) Biosimilars: current status and future directions. Expert Opin Biol Ther 10:1011-1018
2. Schellekens H (2009) Biosimilar therapeutics-what do we need to consider? NDT Plus 2:i27-i36
3. Declerck PJ, Darendeliler F, Goth M et al (2010) Biosimilars: controversies as illustrated by rhGH. Curr Med Res Opin 26:1219-1229
4. European Medicines Agency (2006) Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues. European Medicines Agency, London
5. European Medicines Agency (2006) Annex guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues. Guidance on similar medicinal products containing somatropin. European Medicines Agency, London
6. Zuniga L, Calvo B (2010) Biosimilars approval process. Regul Toxicol Pharmacol 56:374-377
7. de Joncheere K, Rietveld A, Huttin C (2002) Experiences with generics. Int J Risk Safety Med 15:101-109 (Pubitemid 36398733)
8. King DR, Kanavos P (2002) Encouraging the use of generic medicines: implications for transition economies. Croat Med J 43:462-469 (Pubitemid 34976432)
9. Mellstedt H (2010) The future of biosimilars. Hosp Pharm Eur 49:33-34
10. Grabowski H, Cockburn I, Long G (2006) The market for follow-on biologics: how will it evolve? Health Aff 25:1291-1301 (Pubitemid 44497628)
11. Long M, Trout J, Akpinar P (2009) Biosimilars: HGH to TNFS, how will payers respond? ISPOR 12th Annual European Congress, Paris
12. European Generic Medicines Association (2010) EGA handbook on biosimilar medicines. European Generic Medicines Association, Brussels
13. Oldham T (2006) Strategies for entering the biosimilar market. In: Oldham T (ed) Biosimilars - evolution or revolution? Biopharm Knowledge Publishing, London
14. Siena S, Piccart MJ, Holmes FA et al (2003) A combined analysis of two pivotal randomized trials of a single dose of pegfilgrastim per chemotherapy cycle and daily Filgrastim in patients with stage II-IV breast cancer. Oncol Rep 10:715-724
15. Hughes DA (2010) Biosimilars: evidential standards for health technology assessment. Clin Pharmacol Ther 87:257-261
16. Scottish Medicines Consortium (2010) Epoetin zeta. Scottish Medicines Consortium, Edinburgh
17. Stewart A, Aubrey P, Belsey J (2010) Addressing the health technology assessment of biosimilar pharmaceuticals. Curr Med Res Opin 26:2119-2126